| Customization: | Available |
|---|---|
| Dosage Form: | Powder Injection |
| Dossier: | Ready |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Meropenem For Injection 1g |
| Strength | 1g |
| Packing | 1vial+10ml WFI/box |
| Origin | China |
Meropenem is indicated for the following infections in adults and children caused by a single or multiple meropenem sensitive bacteria:
1. Site of endometritis
2. Pneumonia (including nosocomial pneumonia); Urinary tract infection; Gynecological infection: such as endometritis and pelvic inflammation; Skin soft tissue infection; Meningitis; Sepsis.
3. For the empiric treatment of adult patients with granulocytopenia and fever, this product can be used alone or combined with antiviral drugs or antifungal drugs.
Meropenem alone or in combination with other antimicrobials can be used to treat multiple bacterial infections.
For infants with neutropenia or primary or secondary immune deficiency, there is no experience in the use of this product.
Usage and dosage:
Adults: The dose and time interval should be based on the type of infection, the severity, and the patient's specific condition. The recommended daily dose is as follows:
Pneumonia, urinary tract infections, gynecological infections (such as endometritis), skin or soft tissue infections, given every 8 hours, 500mg each time, intravenously.
For the treatment of patients with nosocomial pneumonia, peritonitis, neutropenia complicated with infection and sepsis, the drug should be given every 8 hours, 1g each time, intravenously.
For patients with meningitis, it is recommended to administer 2g every 8 hours.
Children: Children aged from 3 months to 12 years old shall be prescribed the dose of 10 to 20mg/kg every 8 hours according to the severity of the type of infection, susceptibility to pathogenic bacteria and the specific situation of the patient; children weighing more than 50kg shall be prescribed the dose of adult. For the treatment of children with meningitis, the dose is 40mg/kg every 8 hours. There is currently no experience in the use of renal insufficiency in children.
Infants and young children: Meropenem is not recommended for infants and young children under the age of 3 months because of unclear efficacy and tolerance. Children with abnormal liver and kidney function have not been treated with meropenem.
The duration of intravenous infusion of meropenem should be longer than 5 minutes, and the duration of intravenous infusion should be longer than 15 to 30 minutes. Meropenem injection should be prepared with sterile water for injection (250mg per 5ml) at a concentration of about 50mg/ml.
Meropenem intravenous infusion can be prepared with water for injection or other suitable liquid, and then diluted with suitable liquid to 50~200ml for use.
Meropenem can be dissolved using the following infusion: 0.9% sodium chloride solution, 5% or 10% glucose solution, 5% glucose solution (sodium bicarbonate concentration 0.02%), 0.9% sodium chloride solution and 5% glucose solution, 5% glucose solution (sodium chloride concentration 0.225%), 5% glucose solution (potassium chloride concentration 0.15%), 25% or 10% mannitol solution.
Meropenem should not be mixed with other medications.
1. Use with caution carbapenem antibiotics, penicillins or other β-lactam antibiotics in patients with allergic infection.
2. Dose adjustment is unnecessary for patients with liver insufficiency, and the liver function of patients should be carefully monitored.
3. This product is not recommended for infection caused by methicillin-resistant staphylococcus, and skin test should be carried out for those allergic to penicillin
4. The use of antibiotics may cause mild to life-threatening pseudomembranous colitis. Pseudomemematic colitis caused by Clostridium difficile should be confirmed in patients with diarrhea or increased abdominal pain after meropenem use, and other factors should be carefully considered.
5, when treating pseudomonas aeruginosa infection, drug sensitivity test should be routinely carried out.
6. When meropenem is used in combination with drugs with potential renal toxicity, it should be noted that: this product can be cleared by hemodialysis. If the condition requires continuous use of this product, it is recommended to give full dose after hemodialysis according to the condition to achieve effective plasma concentration; For peritoneal dialysis patients, there is no experience in the use of this product.
7. Meropenem should not be frozen. Shake evenly before use; This product should be used once after preparation.
8. Keep medications out of reach of children.
9. This product is incompatibility with Zidovudine, Ondansetron, multivitamins, doxycycline, diazepam, calcium gluconate, acyclovir and other drugs.
Medication for special population:
Pregnant women should not use this product unless it can be shown that the benefits outweigh the risks to the fetus; It is not recommended for lactating women unless it is proven that the benefits outweigh the risks.
Drug interaction:
1. The combination of probenem and meropenem can competitively activate renal tubule secretion and inhibit renal excretion, resulting in prolonged clearance half-life of meropenem and increased blood concentration, so the combination of meropenem and probenem is not recommended.
2. When used with live typhoid vaccine, it may interfere with the immune response of live typhoid vaccine.
3. It has been reported that the combination of antiepileptic drugs with this product can reduce the plasma concentration of antiepileptic drugs.
Drug overdose This product has not been reported in the literature. In the course of treatment, if there is excessive, especially for patients with renal impairment, the drug should be stopped and symptomatic supportive treatment should be given. Hemodialysis can effectively remove this product.
){kind=link}